|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
A total of 631 patients with glioblastoma (mean age 57.78 ± 14.36 years, 59% of males) were examined in this study, including 438 cases with MPC1 intact (MPC1 copy number segments > - 0.1, 69.4%) and 157 cases with MPC1 deletion (24.9%) tumors.
|
31236818 |
2019 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Consistently, KDM5A expression was elevated in PDA and promoted PDA cell proliferation in vitro and tumor growth in vivo via suppressing the expression of MPC-1.
|
31641207 |
2020 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Kaplan-Meier analysis showed that an MPC1 z-score > 0 distinguished better survival, particularly in IDH-mutant (p < 0.01) but not IDH-wild type tumors.
|
29547090 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Low MPC1 expression was associated with tumor T stage, N stage, and advanced tumor node metastasis stage.
|
29123413 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma.
|
30291323 |
2019 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
MPC1 mRNA levels were decreased in each cancer sample, while a mixture of increased and decreased MPC2 mRNA levels observed in the HCC samples.
|
29805642 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Reduced expression of MPC1 disrupts the transporter function, induces metabolic shift to increase glycolysis, and thus plays important roles in several diseases, including cancer.
|
26895100 |
2016 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Decreased MPC1 expression favorably affects EMT and radioresistance of cancer.
|
30801869 |
2019 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Positive MPC1 or MPC2 expression in cancer tissues was significantly associated with higher OS (P < 0.05).
|
27852261 |
2016 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Low MPC1 expression correlated with poor ICC prognosis and was correlated with tumor invasion and distant metastasis.
|
29286150 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Low MPC1 expression was associated with tumor T stage, N stage, and advanced tumor node metastasis stage.
|
29123413 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of MPC-1 was decreased in PDA cell lines and tissues, and negatively associated with tumor poorer differentiation, lymph nodes metastasis, higher TNM stages, and patients' overall survival (OS).
|
31641207 |
2020 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We further demonstrate that COUP-TFII, which is upregulated in the prostate cancer patient, regulates MPC1 and glycolysis to promote tumor growth and metastasis.
|
26895100 |
2016 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
However, the expression status of MPC1 and MPC2 in prostate cancer (PCA) is unclear.
|
27852261 |
2016 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
However, the role of MPC1 in prostate cancer and the underlying mechanism causing the down-regulation of MPC1 in tumor cells remain to be defined.
|
26895100 |
2016 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Although MPC is composed of two subunits, it has been reported that the MPC1 subunit is specifically associated with poor prognosis in several cancers, including colorectal and prostate cancer.
|
29286150 |
2018 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Here we report our results in a prostate cancer cell line in which the mitochondrial pyruvate carrier 1 (MPC1) gene was knockout.
|
28624784 |
2017 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Here we report our results in a prostate cancer cell line in which the mitochondrial pyruvate carrier 1 (MPC1) gene was knockout.
|
28624784 |
2017 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Although MPC is composed of two subunits, it has been reported that the MPC1 subunit is specifically associated with poor prognosis in several cancers, including colorectal and prostate cancer.
|
29286150 |
2018 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
However, the expression status of MPC1 and MPC2 in prostate cancer (PCA) is unclear.
|
27852261 |
2016 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
However, the role of MPC1 in prostate cancer and the underlying mechanism causing the down-regulation of MPC1 in tumor cells remain to be defined.
|
26895100 |
2016 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Reduced expression of MPC1 disrupts the transporter function, induces metabolic shift to increase glycolysis, and thus plays important roles in several diseases, including cancer.
|
26895100 |
2016 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Decreased MPC1 expression favorably affects EMT and radioresistance of cancer.
|
30801869 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Positive MPC1 or MPC2 expression in cancer tissues was significantly associated with higher OS (P < 0.05).
|
27852261 |
2016 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
MPC1 mRNA levels were decreased in each cancer sample, while a mixture of increased and decreased MPC2 mRNA levels observed in the HCC samples.
|
29805642 |
2018 |